2 Blenrep combos for hard-to-treat myeloma approved for adults in EU
Two combination therapies using Blenrep (belantamab mafodotin) — designed to treat adults with relapsed or refractory multiple myeloma — have been approved in the…
Marisa Wexler, MS, senior science writer—
Articles by Marisa Wexler
Aucatzyl approved in Europe for relapsed/refractory B-ALL
The European Commission has approved Autolus Therapeutics’ cell therapy Aucatzyl (obecabtagene autoleucel) as a treatment for B-cell precursor acute lymphoblastic leukemia (B-ALL), an aggressive…
Verastem’s VS-7375 oral therapy on FDA fast track for pancreatic cancer
The experimental oral medication VS-7375 has been granted fast track designation for advanced pancreatic cancer in the U.S. The Food and Drug Administration (FDA)…
IGI, Abbvie team up to advance myeloma treatment ISB 2001
Ichnos Glenmark Innovation (IGI) is partnering with Abbvie to advance the development of ISB 2001, a multiple myeloma treatment candidate that’s now in…
AML treatment ICT01 granted FDA’s orphan drug status
ICT01, an immune-modulating therapy being developed by Imcheck Therapeutics for acute myeloid leukemia (AML), has been granted orphan drug status by the U.S. Food…
Quemliclustat named orphan drug by FDA for pancreatic cancer
Quemliclustat has been granted an orphan drug designation in the U.S. as a potential treatment for pancreatic cancer. The U.S. Food and Drug Administration…
Stories being shared in honor of Glioblastoma Awareness Day
July 16 marks Glioblastoma Awareness Day (GBM Day), an annual observance dedicated to raising awareness about the rare and aggressive form of brain cancer, promoting…
SENTI-202 granted FDA orphan drug designation for blood cancers
Senti Biosciences‘ experimental cell therapy SENTI-202 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) as a potential therapy…
GLIX1 named FDA orphan drug as potential malignant glioma therapy
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GLIX1, a cancer treatment now in the preclinical stages of development, as…
Medicovestor’s pancreatic cancer therapy named FDA orphan drug
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ADoBind MC001, an experimental treatment for pancreatic cancer that’s being developed…
